Antiviral Therapy and Vaccination Strategies Reduce Hepatitis B Mortality

Mitigating the Global Burden of Chronic Hepatitis B

Chronic hepatitis B virus infection remains a primary driver of global morbidity, contributing significantly to the rising incidence of cirrhosis and liver failure [1, 2]. As of 2022, liver cancer ranks as the third leading cause of cancer-related mortality worldwide, accounting for approximately 7.8% of all cancer deaths [3]. In the United States, nearly two million individuals live with chronic infection, and more than 25,000 infants are born annually at risk of perinatal transmission (infection passed from mother to child during birth) [4]. While universal vaccination has altered the epidemiological landscape, meta-analytic data show that antiviral therapy in highly viremic mothers further reduces transmission risk, yielding a relative risk of 0.3 (95% confidence interval, 0.2 to 0.4) [5]. For practicing physicians, identifying at-risk patients and navigating complex management protocols is essential to prevent long-term complications. The current findings provide a comprehensive framework for the diagnosis, prevention, and clinical management of this persistent global health threat, offering actionable strategies to reduce viral transmission and mitigate end-stage liver disease.

Transmission Dynamics and Perinatal Prevention

Hepatitis B virus (HBV) is a DNA virus that spreads through percutaneous or mucosal exposure to infected blood, semen, or other body fluids. Despite the availability of effective prevention strategies, the global burden remains substantial. In 2022, researchers identified approximately 1.2 million new HBV infections worldwide, with 14,000 of those new cases occurring within the United States. The primary driver of chronic infection on a global scale is mother-to-child transmission during the perinatal period. The risk of this vertical transmission is heavily influenced by the mother's serologic status. For infants born to mothers who are positive for both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), the transmission rate ranges from 70% to 90%. In contrast, the risk drops to between 5% and 20% for infants born to mothers who are HBsAg-positive but HBeAg-negative. Clinical intervention during the first hours of life is highly effective at breaking this cycle of infection, highlighting a critical window for obstetric and pediatric care. The administration of the HBV vaccine and hepatitis B immune globulin (a preparation of antibodies that provides immediate, short-term passive immunity) within 12 to 24 hours of birth prevents approximately 94% of perinatal infections. For pregnant women with high HBV DNA levels, the addition of antiviral therapy further strengthens these preventive measures, reducing the transmission rate to less than 1%. However, significant gaps in implementation persist. Although universal birth-dose vaccination is considered the most effective strategy for eliminating the virus, global coverage for the birth-dose HBV vaccine was only 45% in 2024, leaving more than half of the world's newborns vulnerable to lifelong infection.

Age-Dependent Chronicity and Diagnostic Interpretation

The clinical trajectory of HBV infection is heavily dictated by the age at which the initial exposure occurs, with an estimated 254 million people worldwide currently living with the disease. The risk of developing a chronic infection, clinically defined as the persistence of HBsAg for more than 6 months, is highest among the youngest patients. Specifically, the risk of chronicity is 90% if HBV infection occurs during infancy. This risk decreases as the immune system matures, falling to 30% in children aged 1 to 5 years. For immunocompetent adolescents and adults, the likelihood of the infection becoming chronic is significantly lower, at less than or equal to 5%. Accurate diagnosis and management depend on the precise interpretation of a standard hepatitis serology panel. The presence of HBsAg indicates ongoing infection, serving as the primary marker for both acute and chronic states. Conversely, the presence of the antibody to HBsAg indicates immunity, whether acquired through vaccination or recovery from a previous infection. To distinguish between these states and identify patients who have been exposed to the virus naturally, clinicians must look for the antibody to hepatitis B core antigen, which indicates ongoing or past infection. Beyond these qualitative markers, the quantification of serum HBV DNA levels is essential to measure virus-replication activity. This viral load measurement provides the necessary data to guide antiviral treatment decisions, monitor therapeutic efficacy, and assess the risk of future liver complications.

Staging Liver Disease and Antiviral Management

Chronic HBV infection remains a major global health threat, causing approximately 1.1 million deaths annually. To manage these patients effectively and prevent disease progression, clinicians must accurately assess liver inflammation and fibrosis. This assessment relies on serum alanine aminotransferase (ALT) levels alongside noninvasive diagnostic tools, such as the Fibrosis-4 index (a scoring system that uses age, platelet count, and liver enzyme levels to estimate scarring) and liver elastography (an ultrasound-based procedure that measures liver stiffness). These metrics are critical for determining the urgency of intervention, as untreated chronic HBV infection carries a 5-year cumulative risk of cirrhosis ranging from 8% to 15%. Once cirrhosis is established, the clinical outlook worsens significantly, with an annual hepatocellular carcinoma incidence of 3% to 5% among this patient population. Therapeutic intervention focuses on suppressing viral activity to prevent these end-stage complications. Current antiviral therapies include pegylated interferon alfa and nucleos(t)ide analogues, specifically entecavir or tenofovir. These pharmacological agents effectively suppress HBV DNA replication and reduce the risk of hepatocellular carcinoma by approximately 50%. Clinical guidelines recommend initiating antiviral treatment for all patients with chronic HBV and cirrhosis, regardless of other biomarkers. For patients who have not yet progressed to cirrhosis, treatment is indicated when they present with high HBV DNA levels accompanied by elevated ALT or evidence of significant inflammation or fibrosis. For patients identified as being at high risk for malignancy, rigorous monitoring is essential for early detection and improved survival. The findings emphasize that these individuals should undergo surveillance with ultrasonography and alpha-fetoprotein testing every 6 months. This structured approach to monitoring, combined with targeted antiviral therapy, provides clinicians with a reliable mechanism for reducing the long-term morbidity and mortality associated with chronic infection.

References

1. Sarin SK, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International. 2015. doi:10.1007/s12072-015-9675-4

2. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020. doi:10.1016/s0140-6736(20)30925-9

3. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21834

4. Badell ML, Prabhu M, Dionne J, Tita ATN, Silverman NS. Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in pregnancy: updated guidelines.. American journal of obstetrics and gynecology. 2024. doi:10.1016/j.ajog.2023.12.023

5. Brown RS, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis. Hepatology. 2015. doi:10.1002/hep.28302